All regulations
Nonrulemaking
FDA
Open for Comments
FDA-2026-P-2971
Requests that the FDA declare that the proposed drug product, Conjugated Estrogens Tablets, 0.15 mg is suitable for submission as an ANDA
Documents
5
Comments
0
Description
Open
Key Dates
Comment Period OpensMar 24, 2026
Documents
| Type | Title | Status |
|---|---|---|
Other |
Keywords
CDER
Suitability Petition
Lachman Consulting Services, Inc.
Requests that the FDA declare that the
proposed drug product,
Conjugated Estrogens Tablets, 0.15 mg is
suitable for submission as an ANDA
The listed reference drug product (RLD),
Data from Regulations.gov